Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Qualigen Therapeutics, Inc. (QLGN)

1.24   -0.01 (-0.8%) 01-27 15:59
Open: 1.26 Pre. Close: 1.25
High: 1.27 Low: 1.22
Volume: 65,051 Market Cap: 5(M)

Technical analysis

as of: 2023-01-27 4:47:22 PM
Overall:       
Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 1.88     One year: 2.25
Support: Support1: 1.11    Support2: 0.92
Resistance: Resistance1: 1.61    Resistance2: 1.92
Pivot: 1.3
Moving Average: MA(5): 1.25     MA(20): 1.31
MA(100): 2.1     MA(250): 4.14
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 13.9     %D(3): 14.3
RSI: RSI(14): 40.2
52-week: High: 15.19  Low: 0.49
Average Vol(K): 3-Month: 236 (K)  10-Days: 71 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ QLGN ] has closed above bottom band by 24.3%. Bollinger Bands are 58.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 17 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.27 - 1.28 1.28 - 1.28
Low: 1.2 - 1.21 1.21 - 1.22
Close: 1.23 - 1.24 1.24 - 1.25

Company Description

Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.

Headline News

Fri, 27 Jan 2023
Qualigen Therapeutics Inc (QLGN) Stock Has Fallen -2.38% This Week: Buy, Hold, or Sell? - InvestorsObserver

Wed, 18 Jan 2023
What is the Market's View on Qualigen Therapeutics Inc (QLGN) Stock's Price and Volume Trends Wednesday? - InvestorsObserver

Fri, 13 Jan 2023
Will Qualigen Therapeutics Inc (QLGN) Lag the Rest of the Stocks in the Healthcare Sector? - InvestorsObserver

Wed, 11 Jan 2023
Premarket Mover: Qualigen Therapeutics Inc (QLGN) Down 2.99% - InvestorsObserver

Tue, 10 Jan 2023
Is Qualigen Therapeutics Inc (QLGN) Stock Worth a Buy Tuesday? - InvestorsObserver

Thu, 01 Dec 2022
QLGN: Encouraging Preclinical Data Presented for QN-302 and RAS Inhibitor… - Yahoo Finance

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 4 (M)
Shares Float 4 (M)
% Held by Insiders 9 (%)
% Held by Institutions 5.7 (%)
Shares Short 96 (K)
Shares Short P.Month 92 (K)

Stock Financials

EPS -0.55
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 2.88
Profit Margin (%) 0
Operating Margin (%) -247.9
Return on Assets (ttm) -40
Return on Equity (ttm) -125
Qtrly Rev. Growth 24.7
Gross Profit (p.s.) -1.15
Sales Per Share 1.2
EBITDA (p.s.) -2.96
Qtrly Earnings Growth 0
Operating Cash Flow -14 (M)
Levered Free Cash Flow -4 (M)

Stock Valuations

PE Ratio -2.28
PEG Ratio 0
Price to Book value 0.43
Price to Sales 1.02
Price to Cash Flow -0.38

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date 2020-05-25
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.